American Journal of Medicine Studies
ISSN (Print): 2333-8881 ISSN (Online): 2333-889X Website: http://www.sciepub.com/journal/ajms Editor-in-chief: Apply for this position
Open Access
Journal Browser
Go
American Journal of Medicine Studies. 2014, 2(2), 38-41
DOI: 10.12691/ajms-2-2-3
Open AccessCase Report

Quetiapine Induced Cataract - A Rare Case Report

Rajnish Raj1, , Anuradha Raj2 and Raj Kumar3

1Department of Psychiatry, Govt. Medical College & Rajindra Hospital, Patiala, INDIA

2Department of Ophthalmology, Himalayan Institutes of Medical Sciences, Dehradun, Uttarakhand, INDIA

3Department of Pharmacology, Guru Gobind Singh Medical College (Baba Farid University of Health Sciences), Faridkot INDIA

Pub. Date: June 19, 2014

Cite this paper:
Rajnish Raj, Anuradha Raj and Raj Kumar. Quetiapine Induced Cataract - A Rare Case Report. American Journal of Medicine Studies. 2014; 2(2):38-41. doi: 10.12691/ajms-2-2-3

Abstract

Atypical antipsychotics are increasingly used as first-line treatment for bipolar disorder, in both acute mania and acute depression as well as in maintenance treatment. These have also been shown to be effective as add-on agents and in long term prophylaxis. The most common side effects are dry mouth, sedation, dyslipidemia, weight gain, constipation, altered blood glucose level and extra pyramidal side effects. Quetiapine induced cataract has been reported in animal studies and extrapolation on humans was described as rarity. Hence, the case is reported to highlight quetiapine induced cataract.

Keywords:
bipolar disorder Quetiapine posterior capsular cataract Montgomery Asberg Depression Rating Scale (MADRS) Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) adverse event Lens opacity classification system (LOCS)

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  AstraZeneca Pharmaceuticals LP. Seroquel package insert. Wilmington, DE, AstraZeneca Pharmaceuticals, October, 2013 (http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0584dda8-bc3c-48fe-1a90-79608f78e8a0#ID_1ead488d-26c6-4023-8222-129 ac9cccf40). [Accessed on May 5, 2014].
 
[2]  Sanford, M. and Keating, G.M, Quetiapine a review of its use in the management of bipolar depression, CNS Drugs, 26.435-60.2012.
 
[3]  Kapur, S. and Seeman, P, Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis, Am J Psychiatry, 158. 360-9. 2001.
 
[4]  Pharmacotherapy of psychosis and mania, In: Brunton LL, editor. Goodman and Gilman’s The pharmacological basis of therapeutics. 11th ed. New York: McGraw- Hill,2006, pp 461-500.
 
[5]  Calabrese, J.R., Keck, Jr, P.E., Macfadden, W. et al., A randomized, double- bind, placebo- controlled trial of quetiapine in the treatment of bipolar I or II depression, The BOLDER Study Group, Am J Psychiatry, 162. 1351-60. 2005.
 
[6]  Thase, M.E., Macfadden, W., Weisler, R.H. et al., Efficacy of quetiapine monotherapy in bipolar I and II depression: a double- bind, placebo- controlled study, The BOLDER II Study Group, J Clin Psychopharmacol, 26. 600-9. 2006.
 
[7]  Sachs, G., Chengappa, K.N., Suppes, T. et al., Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind placebo-controlled study, Bipolar Disord, 6. 213-23. 2004.
 
[8]  Thase, M.E, Quetiapine monotherapy for bipolar depression, Neuropsychiatrc Dis Treat, 4. 11-21. 2008.
 
[9]  Jensen, N.H., Rodriguiz, R.M., Caron, M.G. et al., N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5HT1 A agonist, as a putative mediator of quetiapine’s antidepressant activity, Neuropsychopharmacol, 33. 2303-12. 2008.
 
[10]  Fraunfelder, F.T. and Fraunfelder, F.W, Drug induced ocular side effects, 5th ed. Woburn: Butterworth-Heinemann, 2001, pp 824.
 
[11]  Sadock, B.J., Sadock, V.A. and Sussman, N, Kaplan and Sadock’s pocket handbook of psychiatric drug treatment. 6th ed. Wolters Kluwer: Lippincott Williams and Wilkins, New Delhi, 2014, pp 229.
 
[12]  American Psychiatric Association, Diagnostic and statistical manual of mental disorders, 5th ed. American Psychiatric Association, Washington DC, 2013, pp 132-9.
 
[13]  Montgomery, S.A. and Asberg, M, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134. 382-9. 1979.
 
[14]  Goodwin, G.M, Evidence- based guidelines for treating bipolar disorder: revised second edition- recommendations from the British Association for Psychopharmacology, J Psychopharmacol, 23. 346-88. 2009.
 
[15]  Taylor, D., Paton, C. and Kapur, S, Bipolar depression, In: The Maudsley prescribing guidelines in psychiatry, 11th ed. Wiley Blackwell, Great Britain, 2012, pp 185-91.
 
[16]  Stip, E. and Boisjoly, H, Quetiapine: are we overreacting in our concern about cataracts (the beagle effect)? Can J Psychiatry, 44. 503. 1999.
 
[17]  Valibhai, F., Phan, N.B., Still, D.J., True, J, Cataracts and quetiapine, Am J Psychiatry, 158. 966. 2001.
 
[18]  Nasrallah, H.A., Dev, V., Rak, I., Raniwalla, J, Safety update with quetiapine and lenticular examinations: experience with 300,000 patients. In: Abstracts of the 38th Annual Meeting of the American College of Neuropsychopharmacology, Nashiville, Tenn, Am Colleg Neuropharmacol, 1999.
 
[19]  Stahl, S.M, Stahl’s Essential Psychopharmacology, The Prescriber’s Guide, 3rd ed. Cambridge University Press, New Delhi, 2009, pp 460.
 
[20]  The use of the WHO-UMC system for standardized case causality assessment. Accessed at http://www.who-umc.org/Graphics/24734.pdf on June 18th, 2014.
 
[21]  Naranjo C.A., Busto U., Sellers E.M. et al., A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther, 30. 239-45. 1981.